Table 3.
Drugs targeting more than or equal to three common susceptibility pathways.
| Drug | Target pathway | Effect |
|---|---|---|
| Abatacept | Intestinal immune network for IgA production | Selective costimulation modulator |
| Cell adhesion molecules | Antirheumatic | |
| Rheumatoid arthritis | ||
| Adalimumab | Inflammatory bowel disease | Anti-TNF-α antibody |
| Antigen processing and presentation | Antirheumatic | |
| Rheumatoid arthritis | Anti-inflammatory | |
| Anti-human thymocyte | Th1 and Th2 cell differentiation | Immunosuppressant |
| Immunoglobulin (rabbit) | Th17 cell differentiation | |
| Hematopoietic cell lineage | ||
| Belatacept | Allograft rejection | Selective costimulation modulator |
| Intestinal immune network for IgA production | Immunosuppressant | |
| Cell adhesion molecules | Antirheumatic | |
| Bleselumab | Allograft rejection | Anti-CD40 antibody |
| Cell adhesion molecules | Immunosuppressant | |
| Toll-like receptor signaling pathway | ||
| Brepocitinib | Th1 and Th2 cell differentiation | JAK1, TYK2 dual inhibitor |
| Th17 cell differentiation | Anti-inflammatory | |
| JAK-STAT signaling pathway | ||
| Certolizumab pegol | Antigen processing and presentation | Anti-TNF-α antibody |
| Rheumatoid arthritis | Anti-inflammatory | |
| Toll-like receptor signaling pathway | Antirheumatic | |
| Delgocitinib | Th1 and Th2 cell differentiation | JAK inhibitor |
| Th17 cell differentiation | Anti-inflammatory | |
| JAK-STAT signaling pathway | Antipsoriatic | |
| Deucravacitinib | Th1 and Th2 cell differentiation | TYK2 inhibitor |
| Th17 cell differentiation | Anti-inflammatory | |
| JAK-STAT signaling pathway | ||
| Filgotinib | Th1 and Th2 cell differentiation | JAK inhibitor |
| Th17 cell differentiation | Anti-inflammatory | |
| JAK-STAT signaling pathway | ||
| Infliximab | Inflammatory bowel disease | Anti-TNF-α antibody |
| Antigen processing and presentation | Anti-inflammatory | |
| Rheumatoid arthritis | Antirheumatic | |
| Interferon alfa | JAK-STAT signaling pathway | Antineoplastic |
| Measles | Antiviral | |
| Toll-like receptor signaling pathway | Biological response modifier | |
| Iscalimab | Allograft rejection | Anti-CD40 antibody |
| Cell adhesion molecules | ||
| Toll-like receptor signaling pathway | ||
| Teneliximab | Allograft rejection | Anti-CD40 antibody |
| Cell adhesion molecules | Immunosuppressant | |
| Toll-like receptor signaling pathway | ||
| Valategrast | Intestinal immune network for IgA production | ITGA4/ITGB1, ITGA4/ITGB7 dual inhibitor |
| hydrochloride | Cell adhesion molecules | Antiasthmatic |
| Hematopoietic cell lineage | ||
| Phagosome |